miRNA expression in advanced Algerian breast cancer tissues

Tfaily, Mohamad Ali; Nassar, Farah; Sellam, Leila-Sarah; Amir-Tidadini, Zine-Charaf; Asselah, F.; Bourouba, Mehdi; Nasr, Rihab

doi:10.1371/journal.pone.0227928

Cited by 11 publications

(4 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a circulating biomarker, it has been studied in different approaches. In a plasma-based study, it did not show diagnostic value [103]. However, it was upregulated in another study on the blood of BC patients [104].…”

Section: Discussionmentioning

confidence: 94%

In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer

Asberger,

Berner,

Bicker

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Background: Breast cancer is the most common type of cancer worldwide. Cyclin-dependent kinase inhibition is one of the backbones of metastatic breast cancer therapy. However, there are a significant number of therapy failures. This study evaluates the biomarker potential of microRNAs for the prediction of a therapy response under cyclin-dependent kinase inhibition. Methods: This study comprises the analysis of intracellular and extracellular microRNA-expression-level alterations of 56 microRNAs under palbociclib mono as well as combination therapy with letrozole. Breast cancer cell lines BT-474, MCF-7 and HS-578T were analyzed using qPCR. Results: A palbociclib-induced microRNA signature could be detected intracellularly as well as extracellularly. Intracellular miR-10a, miR-15b, miR-21, miR-23a and miR-23c were constantly regulated in all three cell lines, whereas let-7b, let-7d, miR-15a, miR-17, miR-18a, miR-20a, miR-191 and miR301a_3p were regulated only in hormone-receptor-positive cells. Extracellular miR-100, miR-10b and miR-182 were constantly regulated across all cell lines, whereas miR-17 was regulated only in hormone-receptor-positive cells. Conclusions: Because they are secreted and significantly upregulated in the microenvironment of tumor cells, miRs-100, -10b and -182 are promising circulating biomarkers that can be used to predict or detect therapy responses under CDK inhibition. MiR-10a, miR-15b, miR-21, miR-23a and miR-23c are potential tissue-based biomarkers.

show abstract

Section: Discussionmentioning

confidence: 94%

In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer

Asberger,

Berner,

Bicker

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Interestingly, there is no research in the recent literature linking these two miRNAs in BC. The association of hsa-miR-200c and hsa-miR-125b has been studied in a recent work where no significant correlation between these two miRNAs was observed 48 . The hypothesis that we put forward to explain our counter-intuitive result is that in this cohort, the oncogenic function of hsa-miR-200c is stabilized by its high connection with hsa-miR-449a.…”

Section: Resultsmentioning

confidence: 99%

Evidence of antagonistic predictive effects of miRNAs in breast cancer cohorts through data-driven networks

Miglioli

Bakalli

Orso

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Non-coding micro RNAs (miRNAs) dysregulation seems to play an important role in the pathways involved in breast cancer occurrence and progression. In different studies, opposite functions may be assigned to the same miRNA, either promoting the disease or protecting from it. Our research tackles the following issues: (i) why aren’t there any concordant findings in many research studies regarding the role of miRNAs in the progression of breast cancer? (ii) could a miRNA have either an activating effect or an inhibiting one in cancer progression according to the other miRNAs with which it interacts? For this purpose, we analyse the AHUS dataset made available on the ArrayExpress platform by Haakensen et al. The breast tissue specimens were collected over 7 years between 2003 and 2009. miRNA-expression profiling was obtained for 55 invasive carcinomas and 70 normal breast tissue samples. Our statistical analysis is based on a recently developed model and feature selection technique which, instead of selecting a single model (i.e. a unique combination of miRNAs), delivers a set of models with equivalent predictive capabilities that allows to interpret and visualize the interaction of these features. As a result, we discover a set of 112 indistinguishable models (in a predictive sense) each with 4 or 5 miRNAs. Within this set, by comparing the model coefficients, we are able to identify three classes of miRNA: (i) oncogenic miRNAs; (ii) protective miRNAs; (iii) undefined miRNAs which can play both an oncogenic and a protective role according to the network with which they interact. These results shed new light on the biological action of miRNAs in breast cancer and may contribute to explain why, in some cases, different studies attribute opposite functions to the same miRNA.

show abstract

“…The first evidence of miRNA implication in cancer came from its deregulation in human Chronic Lymphocytic Leukemia [ 17 ]. Later accumulating evidence has demonstrated that miRNA dysregulation plays an important role in cancer progression [ 18–21 ]. For example, miR-15a-5p, miR-15b-5p, and miR-16-5p were reported to inhibit NB progression by directly targeting Neuroblastoma MYC Oncogene (MYCN) [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA NHEG1/hsa-miR-665/HMGB1 axis is involved in the regulation of neuroblastoma progression

Zhang

Pan

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Long non-coding (lncRNA) neuroblastoma highly expressed 1 (NHEG1) has been reorganized as a prognostic factor in neuroblastoma (NB), but the molecular mechanisms in the suppression of neuroblastoma remain to be elucidated. In our study, we explored the functional roles of lncRNA NHEG1 in neuroblastoma and the underlying molecular mechanism. We collected NB tumor samples and adjacent normal tissues to compare lncRNA NHEG1 expression. Through bioinformatic target prediction, we selected potential downstream effectors of lncRNA NHEG1 for functional validation in NB cell lines. We observed that lncRNA NHEG1 was significantly upregulated in NB tissues as compared to the normal tissues. In NB tissues, lncRNA NHEG1 expression showed an inverse correlation with hsa-miR-665 (miR-655), but a positive correlation with high mobility group box 1 (HMGB1). In NB cell lines, lncRNA NHEG1 knockdown caused the upregulation of miR-665 and the downregulation of HMGB1. Through a series of functional assays, we further demonstrated that lncRNA Nheg1 knockdown suppressed cell proliferation, migration and invasion of NB cells, which could be rescued by miR-665 inhibitor and HMGB1 overexpression. Together, our data demonstrated that lncRNA NHEG1 serves as a competitive partner to negatively regulate the activity of miR-665, which relieves the inhibition on HMGB1 expression and promotes the aggressive phenotype of neuroblastoma cells. Our study indicates that lncRNA NHEG1/miR-665/HMGB1 axis may play an important role in regulating the aggressiveness and the progression of neuroblastoma.

show abstract

miRNA expression in advanced Algerian breast cancer tissues

Cited by 11 publications

References 52 publications

In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer

In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer

Evidence of antagonistic predictive effects of miRNAs in breast cancer cohorts through data-driven networks

Long non-coding RNA NHEG1/hsa-miR-665/HMGB1 axis is involved in the regulation of neuroblastoma progression

Contact Info

Product

Resources

About